Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Serina Therapeutics said its Independent Safety Monitoring Committee cleared SER-252 to move to Cohort 2 after blinded Cohort 1 showed sustained apomorphine exposure and encouraging motor improvements.
Serina Therapeutics said an Independent Safety Monitoring Committee recommended advancing SER-252 to Cohort 2 after blinded review of Cohort 1 safety and tolerability data. PK observations at the lowest dose were consistent with sustained apomorphine exposure.
Serina Therapeutics said it has reported Cohort 1 observations from its Ser-252 registrational study in advanced Parkinson’s disease and has advanced to Cohort 2.
Serina Therapeutics reports cohort 1 observations from its SER-252 registrational study in advanced Parkinson’s disease and advances to cohort 2.